Market Spotlight: Uterine Cancer
Market Spotlight: Uterine Cancer
$1,318.00
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
- In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
- GlaxoSmithKline’s Jemperli, Merck & Co’s Keytruda, and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes.
- The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in Phase III.
- Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results for Xpovio and Jemperli, and expected sNDA/sBLA PDUFA dates as well as estimated CHMP supplemental opinions for Lenvima and Keytruda.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.3%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
- The US has a substantial lead in the number of uterine neoplasms clinical trials globally. Spain leads the major European markets, while China and Thailand share the top spot in Asia.
- Clinical trial activity in the uterine neoplasms space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
- AstraZeneca and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Chemotherapy
10 Hormone therapy
10 Immunotherapy
10 Palliative care
11 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Multiple Drugs for Uterine Cancer (March 19, 2021)
25 Bavencio for Uterine Cancer (May 30, 2020)
27 Trodelvy for Uterine Cancer (May 13, 2020)
29 DKN-01 for Uterine Cancer (April 23, 2020)
32 KEY UPCOMING EVENTS
33 KEY REGULATORY EVENTS
33 Jemperli Approval Makes Everyone Happy
33 Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?
33 GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
34 EU Fast-Track Loss For GSK’s Dostarlimab
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
36 Sorrento Licenses Novel ADC Approach From Mayo Clinic
36 Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
37 REVENUE OPPORTUNITY
38 CLINICAL TRIAL LANDSCAPE
39 Sponsors by status
40 Sponsors by phase
41 Recent events
43 BIBLIOGRAPHY
44 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of uterine cancer, 2019–28
17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
18 Figure 3: Pipeline drugs for uterine cancer, by company
18 Figure 4: Pipeline drugs for uterine cancer, by drug type
18 Figure 5: Pipeline drugs for uterine cancer, by classification
25 Figure 6: Multiple Drugs for Uterine Cancer (March 19, 2021): Phase III – KEYNOTE-775 (w/Pembrolizumab)
27 Figure 7: Bavencio for Uterine Cancer (May 30, 2020): Phase II – TROPHIMMUN (Gestational Trophoblastic Neoplasias (GTN))
29 Figure 8: Trodelvy for Uterine Cancer (May 13, 2020): Phase I/II – Epithelial Cancer
31 Figure 9: DKN-01 for Uterine Cancer (April 23, 2020): Phase II – Gynecologic Malignancies (P204)
32 Figure 10: Key upcoming events in uterine cancer
35 Figure 11: Probability of success in the solid tumors pipeline
38 Figure 12: Clinical trials in uterine cancer
38 Figure 13: Top 10 drugs for clinical trials in uterine cancer
39 Figure 14: Top 10 companies for clinical trials in uterine cancer
39 Figure 15: Trial locations in uterine cancer
40 Figure 16: Uterine cancer trials status
41 Figure 17: Uterine cancer trials sponsors by phase
LIST OF TABLES
12 Table 1: Incident cases of uterine cancer, 2019–28
14 Table 2: Five-year prevalent cases of uterine cancer, 2019–28
16 Table 3: Marketed drugs for uterine cancer
20 Table 4: Pipeline drugs for uterine cancer in the US
24 Table 5: Multiple Drugs for Uterine Cancer (March 19, 2021)
26 Table 6: Bavencio for Uterine Cancer (May 30, 2020)
28 Table 7: Trodelvy for Uterine Cancer (May 13, 2020)
30 Table 8: DKN-01 for Uterine Cancer (April 23, 2020)
37 Table 9: Historical global sales, by drug ($m), 2016–20
37 Table 10: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Gastrointestinal Stromal Tumor (GIST) 
Sign up to the